Regulus Therapeutics’ (RGLS) Buy Rating Reaffirmed at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock.

Regulus Therapeutics Stock Performance

Shares of RGLS opened at $1.27 on Wednesday. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $3.79. The firm has a market cap of $83.19 million, a P/E ratio of -1.19 and a beta of 1.58. The firm’s 50-day simple moving average is $1.34 and its 200 day simple moving average is $1.49.

Insider Buying and Selling

In other Regulus Therapeutics news, insider Preston Klassen sold 31,445 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $39,620.70. Following the completion of the transaction, the insider now directly owns 36,055 shares in the company, valued at approximately $45,429.30. This trade represents a 46.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Christopher Ray Aker sold 38,547 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the sale, the vice president now owns 54,634 shares in the company, valued at approximately $68,838.84. This represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 223,998 shares of company stock worth $282,237. Corporate insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Regulus Therapeutics

A number of institutional investors have recently modified their holdings of RGLS. Creative Planning acquired a new stake in Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC purchased a new position in Regulus Therapeutics during the third quarter worth about $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter worth approximately $46,000. PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter valued at approximately $95,000. Finally, Velan Capital Investment Management LP bought a new position in Regulus Therapeutics in the 4th quarter valued at $111,000. 92.38% of the stock is owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.